Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Sarcoma 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Melanoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 11Carboplatin 7Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Cetuximab 5Trastuzumab 4Specimen Handling 4Radiotherapy 4Paclitaxel 4Sorafenib 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Goserelin 3Doxorubicin 3Capecitabine 3Biopsy 3sacituzumab govitecan 2darolutamide 2bicalutamide 2Radiotherapy, Intensity-Modulated 2Platinum 2Oxaliplatin 2Leuprolide 2Irinotecan 2Ipilimumab 2Dasatinib 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Salivary Gland Neoplasms × EBC-46 × Clear all
NCT05608876 2025-08-07

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

QBiotics Group Limited

Phase 2 Active not recruiting
15 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡